Neurocrine biosciences, inc. (NBIX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Revenues

886,787

788,087

675,566

605,229

518,554

451,240

380,522

235,100

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sponsored research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

18,897

6,811

7,838

9,217

10,462

13,799

12,689

0

0

0

Total revenues

-

-

-

-

-

-

-

-

-

-

-

0

0

-

15,000

15,000

15,000

19,769

19,769

19,769

19,769

0

730

1,459

2,189

2,919

24,136

32,764

42,603

53,140

42,303

74,580

76,168

77,413

80,751

43,760

0

0

0

Operating expenses:
Cost of sales

8,428

7,428

6,471

5,793

5,039

4,889

4,115

2,997

2,204

1,254

494

61

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

220,642

200,042

179,022

169,226

144,527

155,774

117,031

104,012

88,892

91,827

118,796

117,275

122,270

94,291

93,517

96,963

88,819

81,491

75,180

62,986

54,428

46,425

39,845

37,141

37,507

39,248

39,427

39,797

38,088

37,163

36,068

33,664

33,022

30,951

31,176

31,003

0

0

0

Acquired in-process research and development

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

384,362

354,062

321,793

297,705

277,796

248,932

236,261

219,733

200,492

169,906

137,265

110,886

84,177

68,081

53,352

47,314

38,952

32,480

28,511

21,718

19,315

17,986

16,358

14,940

14,110

13,349

13,318

13,397

13,158

13,437

12,794

13,295

12,973

12,458

13,425

12,716

0

0

0

Cease-use expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

82

209

430

0

0

0

Total operating expenses

654,604

715,804

630,136

595,574

545,212

414,345

387,407

356,742

321,588

292,987

256,555

228,222

206,447

162,372

146,869

144,277

127,771

113,971

103,691

84,704

73,743

64,411

56,203

52,081

51,617

52,597

53,702

54,286

52,338

51,692

48,990

46,865

45,977

43,491

44,810

44,149

0

0

0

Operating income (loss)

232,183

72,283

45,430

9,655

-26,658

36,895

26,858

-33,460

-88,876

-131,361

-189,446

-221,887

-206,447

-147,372

-131,869

-129,277

-112,771

-94,202

-83,922

-64,935

-53,974

-64,411

-55,473

-50,622

-49,428

-49,678

-29,566

-21,522

-9,735

1,448

-6,687

27,715

30,191

33,922

35,941

-389

0

0

0

Other (expense) income:
Gain/(loss) on sale/disposal of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

17

3

-

9

10

15

-4

-5

0

14

37

45

39

20

32

83

169

187

242

218

185

0

0

0

Deferred gain on real estate

-

-

-

-

-

-

-

-

-

-

-

0

0

-

3,398

3,373

3,348

3,325

3,299

3,276

3,252

3,226

3,203

3,179

3,155

3,133

3,110

3,088

3,066

3,042

3,020

2,997

2,975

2,953

2,924

2,903

0

0

0

Interest expense

32,263

31,963

31,643

31,277

30,926

30,530

30,186

29,851

27,027

19,523

12,104

4,767

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized losses (gains) on equity securities

-31,187

-12,987

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment income and other, net

19,309

19,209

18,704

18,020

16,943

15,476

15,013

13,107

10,748

8,342

8,265

6,763

6,272

6,282

2,706

2,582

2,408

1,928

1,541

1,136

797

629

517

434

388

402

447

477

471

489

436

415

420

418

459

292

0

0

0

Other (expense) income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

16

6

13

14

14

14

30

30

36

66

0

0

-

0

Total other expense, net

-44,141

-25,741

-18,724

9,408

-12,283

-15,054

-16,931

-18,502

-17,158

-11,181

-4,649

2,030

6,295

6,282

6,123

5,983

5,770

5,273

4,864

4,437

4,082

3,869

3,733

3,626

3,571

3,588

3,608

3,617

3,571

3,577

3,553

3,611

3,612

3,649

3,632

3,428

0

0

0

Income (loss) before provision for (benefit from) income taxes

188,042

46,542

26,706

19,063

-38,941

21,841

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for (benefit from) income taxes

11,530

9,530

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss)

176,512

37,012

21,105

18,080

-39,171

21,111

9,927

-51,962

-106,034

-142,542

-194,095

-219,857

-200,152

-141,090

-125,746

-123,294

-107,001

-88,929

-79,058

-60,498

-49,892

-60,542

-51,740

-46,996

-45,857

-46,090

-25,958

-17,905

-6,164

5,025

-3,134

31,326

33,803

37,571

39,573

3,039

0

0

0

Other comprehensive income (loss):
Net income (loss)

176,512

37,012

21,105

18,080

-39,171

21,111

9,927

-51,962

-106,034

-142,542

-194,095

-219,857

-200,152

-141,090

-125,746

-123,294

-107,001

-88,929

-79,058

-60,498

-49,892

-60,542

-51,740

-46,996

-45,857

-46,090

-25,958

-17,905

-6,164

5,025

-3,134

31,326

33,803

37,571

39,573

3,039

0

0

0

Unrealized gain (loss) on marketable securities

-1,155

3,345

3,663

3,455

3,465

-82

-1,522

-2,096

-3,462

-1,532

-347

-674

-47

659

422

365

-9

-700

-402

-278

15

-282

-198

-82

-150

7

-28

99

83

85

178

-124

-77

-39

0

0

0

-

-

Comprehensive income (loss)

175,357

40,357

24,768

21,535

-35,706

21,029

8,405

-54,058

-109,496

-144,074

-194,442

-220,531

-200,199

-140,431

-125,324

-122,929

-107,010

-89,629

-79,460

-60,776

-49,877

-60,824

-51,938

-47,078

-46,007

-46,083

-25,986

-17,806

-6,081

5,110

-2,956

31,202

33,726

37,532

0

0

0

-

-

Net income (loss) per share:
Net income (loss) per share, basic

0.40

0.37

0.59

0.56

-1.12

-

0.56

-0.07

-

-

-0.13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.02

0.57

0.04

0.05

0.06

-0.09

Net income (loss) per share, diluted

0.39

0.41

0.56

0.54

-1.12

-

0.52

-0.07

-

-

-0.13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.02

0.56

0.04

0.05

0.06

-0.09

Net loss per share, basic and diluted

-

-

-

-

-

-

-

-

-0.47

-

-

-0.68

-0.90

-

-0.43

-0.46

-0.22

-

-0.40

-0.28

-0.01

-

-0.21

-0.18

-0.17

-

-0.17

-0.18

-0.18

-

-0.05

-0.01

-0.01

-

-

-

-

-

-

Shares used in the calculation of net income (loss) per share:
Weighted average common shares outstanding, basic

92,600

92,160

91,859

91,389

91,100

-

90,555

90,100

-

-

88,325

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

55,264

55,248

55,209

54,983

54,844

54,836

Weighted average common shares outstanding, diluted

97,000

100,975

96,074

94,779

91,100

-

96,798

90,100

-

-

88,325

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

56,462

56,378

56,434

56,114

55,648

54,836

Weighted average common shares outstanding, basic and diluted

-

-

-

-

-

-

-

-

89,526

-

-

88

87,283

-

86,784

86,694

86,497

-

85,856

85,518

80,349

-

75,948

75,879

70,260

-

67,199

66,799

66,600

-

66,342

66,309

63,409

-

-

-

-

-

-

Product sales, net
Revenues

847,600

752,900

645,364

558,561

474,922

409,608

325,056

0

0

-

0

-

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue
Revenues

39,187

35,187

69,502

0

0

-

0

-

-

-

0

-

-

15,000

15,000

15,000

15,000

19,769

19,769

19,769

19,769

0

730

1,459

2,189

2,919

10,177

17,436

25,735

34,243

35,492

66,742

66,951

66,951

66,952

31,071

0

0

0